Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists.

Claff T, Yu J, Blais V, Patel N, Martin C, Wu L, Han GW, Holleran BJ, Van der Poorten O, White KL, Hanson MA, Sarret P, Gendron L, Cherezov V, Katritch V, Ballet S, Liu ZJ, Müller CE, Stevens RC.

Sci Adv. 2019 Nov 27;5(11):eaax9115. doi: 10.1126/sciadv.aax9115. eCollection 2019 Nov.

2.

Interplay between intracellular loop 1 and helix VIII of the angiotensin II type 2 receptor controls its activation.

Connolly A, Holleran BJ, Simard É, Baillargeon JP, Lavigne P, Leduc R.

Biochem Pharmacol. 2019 Oct;168:330-338. doi: 10.1016/j.bcp.2019.07.018. Epub 2019 Jul 23.

PMID:
31348898
3.

N-Guanidyl and C-Tetrazole Leu-Enkephalin Derivatives: Efficient Mu and Delta Opioid Receptor Agonists with Improved Pharmacological Properties.

Beaudeau JL, Blais V, Holleran BJ, Bergeron A, Piñeyro G, Guérin B, Gendron L, Dory YL.

ACS Chem Neurosci. 2019 Mar 20;10(3):1615-1626. doi: 10.1021/acschemneuro.8b00550. Epub 2019 Jan 23.

PMID:
30614675
4.

GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation.

Tutunea-Fatan E, Abd-Elrahman KS, Thibodeau JF, Holterman CE, Holleran BJ, Leduc R, Kennedy CRJ, Gros R, Ferguson SSG.

Sci Rep. 2018 Jul 30;8(1):11415. doi: 10.1038/s41598-018-29876-8.

5.

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms.

St-Pierre D, Cabana J, Holleran BJ, Besserer-Offroy É, Escher E, Guillemette G, Lavigne P, Leduc R.

Biochem Pharmacol. 2018 Aug;154:104-117. doi: 10.1016/j.bcp.2018.04.021. Epub 2018 Apr 20.

PMID:
29684376
6.

Synthesis and Evaluation of a 64Cu-Conjugate, a Selective δ-Opioid Receptor Positron Emission Tomography Imaging Agent.

Pirisedigh A, Blais V, Ait-Mohand S, Abdallah K, Holleran BJ, Leduc R, Dory YL, Gendron L, Guérin B.

Org Lett. 2017 Apr 21;19(8):2018-2021. doi: 10.1021/acs.orglett.7b00575. Epub 2017 Apr 3.

PMID:
28368122
7.

Characterization of Angiotensin II Molecular Determinants Involved in AT1 Receptor Functional Selectivity.

Domazet I, Holleran BJ, Richard A, Vandenberghe C, Lavigne P, Escher E, Leduc R, Guillemette G.

Mol Pharmacol. 2015 Jun;87(6):982-95. doi: 10.1124/mol.114.097337. Epub 2015 Mar 25.

PMID:
25808928
8.

Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

Sainsily X, Cabana J, Holleran BJ, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2014 Nov 15;92(2):280-8. doi: 10.1016/j.bcp.2014.08.023. Epub 2014 Aug 29.

PMID:
25175740
9.

Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

Sainsily X, Cabana J, Boulais PE, Holleran BJ, Escher E, Lavigne P, Leduc R.

Biochem Pharmacol. 2013 Dec 1;86(11):1584-93. doi: 10.1016/j.bcp.2013.09.015. Epub 2013 Sep 29.

PMID:
24084430
10.

Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.

Yan L, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

J Biol Chem. 2010 Jan 22;285(4):2284-93. doi: 10.1074/jbc.M109.077180. Epub 2009 Nov 23.

11.

The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.

Domazet I, Martin SS, Holleran BJ, Morin ME, Lacasse P, Lavigne P, Escher E, Leduc R, Guillemette G.

J Biol Chem. 2009 Nov 13;284(46):31953-61. doi: 10.1074/jbc.M109.051839. Epub 2009 Sep 22.

12.

Activation induces structural changes in the liganded angiotensin II type 1 receptor.

Clément M, Cabana J, Holleran BJ, Leduc R, Guillemette G, Lavigne P, Escher E.

J Biol Chem. 2009 Sep 25;284(39):26603-12. doi: 10.1074/jbc.M109.012922. Epub 2009 Jul 27.

13.

Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

Holleran BJ, Domazet I, Beaulieu ME, Yan LP, Guillemette G, Lavigne P, Escher E, Leduc R.

Biochem Pharmacol. 2009 Apr 15;77(8):1374-82. doi: 10.1016/j.bcp.2009.01.013. Epub 2009 Jan 29.

PMID:
19426676
14.

The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.

Domazet I, Holleran BJ, Martin SS, Lavigne P, Leduc R, Escher E, Guillemette G.

J Biol Chem. 2009 May 1;284(18):11922-9. doi: 10.1074/jbc.M808113200. Epub 2009 Mar 9.

15.

Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor.

Proulx CD, Holleran BJ, Boucard AA, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2008 Sep;74(3):552-61. doi: 10.1124/mol.108.045054. Epub 2008 May 28.

PMID:
18509066
16.

Biological properties and functional determinants of the urotensin II receptor.

Proulx CD, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R.

Peptides. 2008 May;29(5):691-9. Epub 2007 Nov 17. Review.

PMID:
18155322
17.

Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method.

Martin SS, Holleran BJ, Escher E, Guillemette G, Leduc R.

Mol Pharmacol. 2007 Jul;72(1):182-90. Epub 2007 Apr 19.

PMID:
17446269
18.

Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

Holleran BJ, Beaulieu ME, Proulx CD, Lavigne P, Escher E, Leduc R.

Biochem J. 2007 Feb 15;402(1):51-61.

20.
21.

Bilateral apical carcinomas of the lung. A case report.

Holleran BJ, Okinaka AJ.

J Thorac Cardiovasc Surg. 1969 Jun;57(6):853-6. No abstract available.

PMID:
5770470

Supplemental Content

Loading ...
Support Center